The study introduces a novel senolytic immunotherapy, SenoVax™, which demonstrated promising results in enhancing anti-tumor immune responses in mice bearing syngeneic Lewis Lung Cancer (LLC ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback